骨肉瘤
基因敲除
癌症研究
抗药性
下调和上调
细胞培养
常用化疗药物
化疗
长非编码RNA
细胞
药品
生物
医学
基因
药理学
内科学
微生物学
遗传学
作者
Luoying Li,Yifan Zhang,Yan Gao,Yaqi Hu,Rui Wang,Shuwen Wang,Yuanyang Li,Yumin He,Chengfu Yuan
标识
DOI:10.1038/s41417-022-00581-z
摘要
The most prevalent form of primary osseous malignant tumor in adolescents and children is osteosarcoma (OS). A combination of surgery and neoadjuvant/post-surgery chemotherapy is currently the standard therapy. While the chemoresistance associated with OS generally leads to poor efficacy of therapeutic agents, the relevant molecular interaction is still elusive. Here, the lncRNA (long non-coding RNA) SNHG14 was found to be significantly upregulated in the nutlin3a-resistant OS cell line NR-SJSA1 and contributes to treatment resistance by suppressing ferroptosis. In NR-SJSA1 cells, knockdown of LncRNA SNHG14 resulted in a reversal of drug resistance and activation of ferroptosis, which disappeared when ferrostatin-1, a ferroptosis inhibitor, was added. Mechanistically, lncRNA SNHG14 targeted and down-regulated the expression of miR-206, further affecting the common ferroptosis inhibitor SLC7A11, and preventing NR-SJSA1 cells from undergoing ferroptosis. In conclusion, our findings highlight the involvement of lncRNA SNHG14 in ferroptosis and chemotherapy resistance of nutlin3a-resistant NR-SJSA1 cells, thus shedding new insight on how to overcome drug resistance in osteosarcoma cells and improve treatment efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI